<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25074046</article-id><article-id pub-id-type="pmc">4261980</article-id><article-id pub-id-type="publisher-id">4275</article-id><article-id pub-id-type="doi">10.1186/ar4675</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Paramarta</surname><given-names>Jacqueline E</given-names></name><address><email>j.e.paramarta@amc.uva.nl</email></address><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Baeten</surname><given-names>Dominique L</given-names></name><address><email>d.l.baeten@amc.uva.nl</email></address><xref ref-type="aff" rid="Aff9"/></contrib><aff id="Aff9">Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Meibergdreef 9 1105 AZ, Amsterdam, the Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>16</volume><issue>4</issue><elocation-id>R160</elocation-id><history><date date-type="received"><day>3</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Paramarta and Baeten; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>In this study, we evaluated the clinical relevance of serum drug levels and antidrug antibodies (ADAbs) with regard to response to treatment, as well as to relapse upon treatment discontinuation, in peripheral spondyloarthritis (pSpA) patients treated with adalimumab.</p></sec><sec><title>Methods</title><p>The study included 26 pSpA patients treated with adalimumab for either 12&#x000a0;weeks (<italic>n</italic>&#x02009;=&#x02009;12) or 24&#x000a0;weeks (<italic>n</italic>&#x02009;=&#x02009;14) in a randomized controlled trial. Patients achieving inactive disease measured by Ankylosing Spondylitis Disease Activity Score (ASDAS) at the end of the treatment period were classified as responders. Clinical characteristics, serum trough adalimumab levels and ADAbs were assessed at the end of the treatment period and at follow-up (upon relapse or, in absence of relapse, at 16&#x000a0;weeks after discontinuation).</p></sec><sec><title>Results</title><p>Serum adalimumab levels measured 2&#x000a0;weeks after the last adalimumab administration ranged from &#x0003c;0.002 to 23.0&#x000a0;&#x003bc;g/ml, with a median of 11.5&#x000a0;&#x003bc;g/ml. These levels were associated with neither response to treatment or disease activity measurements at the end of treatment nor with the occurrence of relapse and time to relapse after discontinuation of treatment. Antiadalimumab ADAbs were present in 23% of the patients at end of treatment and in 35% at follow-up after treatment discontinuation, indicating that ADAbs were masked by the presence of the drug in some patients. However, ADAbs at the end of treatment and at follow-up were not different between responders and nonresponders and were not associated with relapse upon discontinuation of treatment.</p></sec><sec><title>Conclusions</title><p>There is no clear association between adalimumab serum levels or antiadalimumab ADAbs with clinical response to treatment or with relapse upon treatment discontinuation in pSpA.</p></sec><sec><title>Trial registration</title><p>Netherlands Trial Register ID:
<ext-link ext-link-type="uri" xlink:href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1806">NTR1806</ext-link> (registered 7 May 2009)</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Tumour necrosis factor (TNF) inhibition is a highly effective treatment for axial and peripheral spondyloarthritis (SpA)
[<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. However, a significant proportion of patients fails to respond or does not tolerate the treatment because of side effects. The reasons for nonresponse or for intolerance are multiple, potentially including the development of antidrug antibodies (ADAbs) directed towards the TNF blocker. It has been proposed that ADAbs may reduce therapeutic responses, either by increasing the clearance of the TNF inhibitor
[<xref ref-type="bibr" rid="CR6">6</xref>] or by direct neutralisation of the functional part of the drug
[<xref ref-type="bibr" rid="CR7">7</xref>]. Accordingly, authors of recent reviews have suggested that monitoring of serum drug levels and ADAbs would be a promising tool for personalised cost-effective usage of biological therapies in immune-mediated inflammatory diseases (IMIDs)
[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Most studies on the immunogenicity of TNF blockers have been performed in rheumatoid arthritis and Crohn&#x02019;s disease. In SpA, the available studies on immunogenicity have yielded conflicting results. Regarding infliximab and adalimumab, some research groups have reported that ADAbs towards these TNF inhibitors are associated with decreased clinical response and increased risk of hypersensitivity reactions
[<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], whereas others have not found this association and have even concluded that serum anti-TNF drug levels are not associated with response to treatment
[<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. For etanercept, these ADAbs have not been detected, and it has been shown that the serum drug levels are similar in responders and nonresponders
[<xref ref-type="bibr" rid="CR19">19</xref>]. Recently, golimumab ADAbs did not appear to have a major role in treatment success or failure
[<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Moreover, the authors of a recent meta-analysis of anti-TNF ADAbs in various IMIDs concluded that there was no relevant association of ADAbs with efficacy in SpA
[<xref ref-type="bibr" rid="CR22">22</xref>]. This corresponds to the clinical experience that treatment failure after TNF blockade is similar among the various TNF blockers
[<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], both the ones which do and those that do not cause the development of ADAbs according to the results of the aforementioned studies
[<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>These conflicting results may be related to the diversity of methods used and the timing of the measurement to evaluate the ADAbs, as well as to the fact that the presence of detectable serum drug levels may mask the detection of ADAbs
[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The latter issue can be avoided by the use of novel assay methods
[<xref ref-type="bibr" rid="CR25">25</xref>] and/or by assessing the ADAbs several weeks after stopping the TNF inhibitor. In this study, we assessed the potential clinical relevance of serum drug levels and ADAbs measured at the end of the treatment period as well as at a drug-free follow-up examination after a double-blind, placebo-controlled, randomized clinical trial (RCT) with adalimumab in patients with peripheral SpA (pSpA)
[<xref ref-type="bibr" rid="CR5">5</xref>]. We correlated these serum levels with both clinical response at the end of treatment and relapse upon discontinuation of the TNF inhibitor.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study patients</title><p>Twenty-six patients from our RCT with adalimumab in peripheral arthritis in SpA who did not fulfil the criteria for ankylosing spondylitis (AS) or psoriatic arthritis (PsA)
[<xref ref-type="bibr" rid="CR5">5</xref>] were included in this study. The patients fulfilled the European Spondyloarthritis Study Group (ESSG) criteria
[<xref ref-type="bibr" rid="CR26">26</xref>] and/or the Amor <italic>et al</italic>. criteria
[<xref ref-type="bibr" rid="CR27">27</xref>] and had active disease at the time of inclusion. They were treated with either placebo (<italic>n</italic>&#x02009;=&#x02009;12) or adalimumab (<italic>n</italic>&#x02009;=&#x02009;14) for 12&#x000a0;weeks, followed by a 12-week open-label phase with adalimumab for all patients
[<xref ref-type="bibr" rid="CR5">5</xref>]. After this period, adalimumab was discontinued. Patients were allowed to continue treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (&#x02264;10&#x000a0;mg/day prednisone or equivalent), methotrexate and sulfasalazine at a stable dosage throughout the study. After discontinuation of the TNF inhibitor, patients were prospectively followed for 16&#x000a0;weeks and seen for a relapse visit upon worsening of symptoms or, in the absence of relapse, at the 16-week follow-up visit. The following disease activity parameters were measured: patient&#x02019;s and physician&#x02019;s global assessment of disease activity, 68/66 tender joint count (TJC) and swollen joint count (SJC), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score, Ankylosing Spondylitis Disease Activity Score (ASDAS), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level. Responders were defined as patients achieving inactive disease based on ASDAS at the end of treatment
[<xref ref-type="bibr" rid="CR28">28</xref>]. Relapse was defined as an increase of at least one swollen joint or an increase by at least two points in the patient&#x02019;s or physician&#x02019;s global assessment of disease activity or BASDAI score
[<xref ref-type="bibr" rid="CR29">29</xref>]. Fourteen patients (53.8%) reached ASDAS-defined inactive disease at the end of the treatment period. Nineteen patients (73.1%) had a disease relapse within 16&#x000a0;weeks after discontinuation of adalimumab, with a mean time to relapse of 10.0&#x02009;&#x000b1;&#x02009;3.2&#x000a0;weeks. The characteristics of the patients have been published previously
[<xref ref-type="bibr" rid="CR29">29</xref>]. Written informed consent was obtained from each patient before study-related procedures were performed, and the study was approved by the Medical Ethics Committee of the Academic Medical Center/University of Amsterdam.</p></sec><sec id="Sec4"><title>Assessment of serum adalimumab levels</title><p>Serum samples were obtained 2&#x000a0;weeks after the last adalimumab administration (<italic>n</italic>&#x02009;=&#x02009;26) and at follow-up (upon relapse or 16&#x000a0;weeks after discontinuation in the absence of relapse (<italic>n</italic>&#x02009;=&#x02009;25). Trough serum adalimumab concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) developed by Wolbink <italic>et al</italic>. as previously described and as accredited by the Dutch Accreditation Council/Dutch Accreditation Board for Medical Laboratories (RvA/CCKL) according to the International Standardization Organization (ISO) guideline ISO17025
[<xref ref-type="bibr" rid="CR30">30</xref>]. The detection limit of the assay is approximately 0.001&#x000a0;&#x003bc;g/ml; serum adalimumab levels &#x0003c;5.0&#x000a0;&#x003bc;g/ml were designated low, as previously described
[<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec5"><title>Assessment of antibodies against adalimumab</title><p>The same serum samples were analysed by radioimmunoassay (Sanquin) to detect the presence of antiadalimumab antibodies as previously described
[<xref ref-type="bibr" rid="CR30">30</xref>]. Dilution of 1&#x000a0;&#x003bc;l of serum in phosphate-buffered saline/0.3% bovine serum albumin (<italic>pro analysi</italic> buffer) was followed by overnight incubation with 1&#x000a0;mg of Sepharose-immobilized protein A (GE Healthcare, Chalfont St Giles, UK) in a final volume of 800&#x000a0;&#x003bc;l. Next, the samples were washed with phosphate-buffered saline 0.005% polysorbate. The antiadalimumab binding was determined by overnight incubation with 20,000 disintegrations per minute (dpm (approximately 1&#x000a0;ng)) of <sup>125</sup>I-labeled F(ab)<sub>2</sub> adalimumab fragments diluted in Freeze buffer (Sanquin, Amsterdam, the Netherlands). Unbound label was removed by washing, and protein A&#x02013;bound radioactivity was measured. Antiadalimumab levels were expressed in arbitrary units (AU; 1&#x000a0;AU&#x02009;&#x02248;&#x02009;12&#x000a0;ng) using a serum containing antiadalimumab as standard. The mean cutoff value derived from 100 healthy donors was set at 12&#x000a0;AU/ml.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p>The data are presented as medians and interquartile ranges (IQRs). Mann&#x02013;Whitney <italic>U</italic> tests were used to compare differences in serum levels in cases of unpaired samples, and Wilcoxon signed-rank tests were performed in cases of paired samples. &#x003c7;<sup>2</sup> tests were used for categorical variables. Logistic regression analyses were conducted to examine associations between the ASDAS response, relapse status and trough serum adalimumab and antiadalimumab ADAb levels. Correlations between the serum measurements and the clinical disease activity measurements were assessed using Spearman&#x02019;s correlation tests. All statistical tests were two-sided, and <italic>P</italic>-values &#x0003c;0.05 were considered statistically significant.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Clinical response to treatment and relapse after anti-TNF treatment discontinuation are independent of trough serum adalimumab levels</title><p>Trough serum adalimumab levels at the end of the treatment period (2&#x000a0;weeks after the last injection) ranged from &#x0003c;0.002 to 23.0&#x000a0;&#x003bc;g/ml (median&#x02009;=&#x02009;11.5&#x000a0;&#x003bc;g/ml). Seven patients (26.9%) had serum adalimumab levels &#x0003c;5.0&#x000a0;&#x003bc;g/ml. Levels were not different between patients treated with adalimumab for 12 or 24&#x000a0;weeks (<italic>P</italic>&#x02009;=&#x02009;0.292) (Figure&#x000a0;
<xref rid="Fig1" ref-type="fig">1</xref>A). There were no significant differences in trough serum adalimumab levels between responders (median&#x02009;=&#x02009;12.6 (IQR&#x02009;=&#x02009;7.3 to 16.2) &#x003bc;g/ml) and nonresponders (9.3 (3.1 to 14.5) &#x003bc;g/ml) as defined by the achievement of inactive disease defined by ASDAS (<italic>P</italic>&#x02009;=&#x02009;0.237) (Figure&#x000a0;
<xref rid="Fig1" ref-type="fig">1</xref>B). Serum adalimumab levels also did not correlate with end-of-study disease activity parameters such as patient&#x02019;s global assessment (Figure&#x000a0;
<xref rid="Fig1" ref-type="fig">1</xref>C) and physician&#x02019;s global assessment of disease activity, TJC, SJC, BASDAI score, ASDAS, ESR (data not shown) and CRP level (Figure&#x000a0;
<xref rid="Fig1" ref-type="fig">1</xref>D). Moreover, adalimumab levels at the end of treatment were not different between patients with vs. without subsequent relapse upon discontinuation of therapy (<italic>P</italic>&#x02009;=&#x02009;0.931) (Figure&#x000a0;
<xref rid="Fig2" ref-type="fig">2</xref>A) and were not correlated with time to relapse (<italic>P</italic>&#x02009;=&#x02009;0.984) (Figure&#x000a0;
<xref rid="Fig2" ref-type="fig">2</xref>B). Taken together, these data indicate that the amplitude and/or duration of clinical response to adalimumab in pSpA patients are not related to trough serum adalimumab levels.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Clinical response to treatment is independent of trough serum adalimumab levels.</bold> Trough serum adalimumab levels at the end of treatment (2&#x000a0;weeks after the last injection) were not different between patients treated with 12 or 24&#x000a0;weeks of adalimumab <bold>(A)</bold> or between responders and nonresponders <bold>(B)</bold> Median (interquartile range). Also, there was no correlation between these drug levels and clinical disease activity parameters such as patient&#x02019;s global assessment of disease activity measured on a 100-mm visual analogue scale (VAS) <bold>(C)</bold> or C-reactive protein (CRP) level <bold>(D)</bold>.</p></caption><graphic xlink:href="13075_2013_4275_Fig1_HTML" id="d30e562"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Relapse after treatment discontinuation is independent of trough serum adalimumab levels.</bold> Trough serum adalimumab levels at the end of treatment (2&#x000a0;weeks after the last injection) were similar between patients who did and those who did not relapse after discontinuation of the tumour necrosis factor inhibitor (TNFi) <bold>(A)</bold> Median (interquartile range). Neither was there a correlation between the drug levels and time to relapse <bold>(B)</bold>.</p></caption><graphic xlink:href="13075_2013_4275_Fig2_HTML" id="d30e581"/></fig></p></sec><sec id="Sec9"><title>Clinical response to treatment and relapse after anti-TNF treatment discontinuation are independent of presence of antiadalimumab antidrug antibodies</title><p>At the end of the treatment period, 6 (23.1%) of 26 patients tested positive for serum antiadalimumab ADAbs: 4 were clearly positive, with titres ranging from 89 to 2,320&#x000a0;AU/ml, and 2 were borderline positive, both with a titre of 15&#x000a0;AU/ml. The presence of detectable antiadalimumab ADAb levels was similar between patients treated with adalimumab for 12&#x000a0;weeks (4 (33.3%) of 12 patients) or for 24&#x000a0;weeks (2 (14.3%) of 14 patients) (<italic>P</italic>&#x02009;=&#x02009;0.250) (Figure&#x000a0;
<xref rid="Fig3" ref-type="fig">3</xref>A) and between responders (3 (21.4%) of 14 patients) and nonresponders (3 (25.0%) 12 patients) (<italic>P</italic>&#x02009;=&#x02009;0.829) (Figure&#x000a0;
<xref rid="Fig3" ref-type="fig">3</xref>B). The antiadalimumab ADAb titres did not correlate with the various disease activity measurements (data not shown). Finally, the number of patients who tested positive for antiadalimumab ADAbs was not different between those with vs. without subsequent relapse upon discontinuation of therapy (<italic>P</italic>&#x02009;=&#x02009;0.518) (Figure&#x000a0;
<xref rid="Fig4" ref-type="fig">4</xref>A), nor was there a difference in time to relapse (<italic>P</italic>&#x02009;=&#x02009;0.488) (Figure&#x000a0;
<xref rid="Fig4" ref-type="fig">4</xref>B). As for the trough serum adalimumab levels, our data do not provide any evidence that antiadalimumab ADAbs have a significant impact on the amplitude and/or the duration of clinical response to adalimumab in pSpA.<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Clinical response to treatment is independent of the presence of antiadalimumab antidrug antibodies.</bold> Antiadalimumab antidrug antibodies (ADAbs) at the end of treatment, 2&#x000a0;weeks after the last injection, were not different between patients treated with 12 vs. 24&#x000a0;weeks of adalimumab <bold>(A)</bold> or between responders vs. nonresponders <bold>(B)</bold>.</p></caption><graphic xlink:href="13075_2013_4275_Fig3_HTML" id="d30e629"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Relapse after treatment discontinuation is independent of the presence of antiadalimumab antidrug antibodies.</bold> Antiadalimumab antidrug antibodies (ADAbs) at the end of treatment, 2&#x000a0;weeks after the last injection, were not different between patients who did vs. those who did not relapse after discontinuation of adalimumab <bold>(A)</bold>. There was no difference in time to relapse in patients who tested positive vs. those who tested negative for antiadalimumab ADAbs <bold>(B)</bold> Median (interquartile range).</p></caption><graphic xlink:href="13075_2013_4275_Fig4_HTML" id="d30e647"/></fig></p></sec><sec id="Sec10"><title>Antiadalimumab ADAbs can be masked by presence of adalimumab; &#x02018;unmasked&#x02019; antiadalimumab ADAbs do not correlate with clinical response to treatment</title><p>As several factors can bias the measurement and/or interpretation of ADAbs, we conducted additional analyses to assess the potential clinical relevance of these antibodies. First, there was a negative correlation between the antiadalimumab ADAb titres and serum trough adalimumab levels (<italic>R</italic>&#x02009;=&#x02009;-0.709, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). This may be explained by the fact that ADAbs contribute to the clearance of the drug or, alternatively, by the fact that serum adalimumab levels may interfere with the measurement of the ADAbs
[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. To investigate the latter possibility, we obtained additional serum samples from 25 of 26 patients at a median follow-up of 10.1 (IQR&#x02009;=&#x02009;8.3 to 14.0) weeks after interruption of the adalimumab treatment. At this time point, the median serum adalimumab level was 1.7 (IQR&#x02009;=&#x02009;0.2 to 4.4) &#x003bc;g/ml, which was significantly lower than the level at the end of treatment (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Figure&#x000a0;
<xref rid="Fig5" ref-type="fig">5</xref>A). Measurement of antiadalimumab ADAbs at the same time point, which allowed us to exclude interference of circulating adalimumab levels, showed that the four patients with high ADAbs at the end of treatment maintained high ADAb levels after interruption of treatment, whereas the titres tended to increase over time in the three patients with low ADAb titres at the end of treatment (Figure&#x000a0;
<xref rid="Fig5" ref-type="fig">5</xref>B). Additionally, three patients without detectable ADAbs at the end of treatment had titres between 15 and 57&#x000a0;AU/ml at follow-up, confirming that low to intermediate levels of ADAbs may be partially masked by circulating adalimumab. However, these &#x02018;unmasked&#x02019; antiadalimumab ADAbs were not different between responders (33.3% positive for &#x02018;unmasked&#x02019; antiadalimumab) and nonresponders (40.0% positive for &#x02018;unmasked&#x02019; antiadalimumab) (<italic>P</italic>&#x02009;=&#x02009;0.734) or between patients who did vs. those who did not experience relapse after treatment discontinuation (42.1% and 16.7%, respectively; <italic>P</italic>&#x02009;=&#x02009;0.258). The titres of the &#x02018;unmasked&#x02019; ADAbs were not correlated with either the various disease activity measurements or the time to relapse (data not shown).<fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>Antiadalimumab antidrug antibodies can be masked by the presence of adalimumab in serum.</bold> Trough serum adalimumab levels <bold>(A)</bold> and antiadalimumab antidrug antibody (ADAb) titres <bold>(B)</bold> at the end of treatment (2&#x000a0;weeks after the last injection) and at follow-up (upon relapse or, in absence of relapse, at 16&#x000a0;weeks after discontinuation). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 assessed by Wilcoxon signed-rank test.</p></caption><graphic xlink:href="13075_2013_4275_Fig5_HTML" id="d30e701"/></fig></p><p>Second, we investigated the effect of concomitant treatment with disease-modifying antirheumatic drugs (DMARDs) on ADAbs because this has been described to reduce the frequency of ADAb formation
[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Although numerically different, there was no statistical difference in antiadalimumab ADAb positivity between patients taking DMARDs (5 (33.3%) of 15 patients,) vs. patients not taking DMARDs (1, (9.1%) of 11 patients) (<italic>P</italic>&#x02009;=&#x02009;0.147) (Figure&#x000a0;
<xref rid="Fig6" ref-type="fig">6</xref>A). Strikingly, this difference was no longer present when we analysed the &#x02018;unmasked&#x02019; antiadalimumab ADAbs: 5 (35.7%) of 14 patients who were positive in the no-DMARDs group vs. 4 (36.4%) of 11 patients in the DMARDs group (<italic>P</italic>&#x02009;=&#x02009;0.973) (Figure&#x000a0;
<xref rid="Fig6" ref-type="fig">6</xref>B).<fig id="Fig6"><label>Figure 6</label><caption><p>
<bold>The effect of disease-modifying antirheumatic drugs on antiadalimumab antidrug antibodies.</bold> At the end of treatment (2&#x000a0;weeks after the last injection), antiadalimumab antidrug antibodies (ADAbs) were less often observed in patients who used concomitant disease-modifying antirheumatic drugs (DMARDs) compared than in patients who did not use any DMARDs, although this finding was not statistically significant <bold>(A)</bold>. However, this difference disappeared when we assessed the &#x02018;unmasked&#x02019; antiadalimumab ADAbs at follow-up <bold>(B)</bold>.</p></caption><graphic xlink:href="13075_2013_4275_Fig6_HTML" id="d30e746"/></fig></p></sec><sec id="Sec11"><title>Adalimumab levels and antiadalimumab antidrug antibodies in patients with generalized drug reactions</title><p>Two patients developed a generalized skin reaction upon initiation of adalimumab during the study. Both patients were able to continue adalimumab treatment after administration of topical corticosteroids and treatment with oral antihistamine. One of these patients had a low serum trough adalimumab level (&#x0003c;0.002&#x000a0;&#x003bc;g/ml) and tested positive for antiadalimumab ADAbs with a titre of 2,320&#x000a0;AU/ml. The second patient had a serum trough adalimumab level of 17.5&#x000a0;&#x003bc;g/ml and tested negative for antiadalimumab ADAbs both at the end of the study and at follow-up after interruption of treatment. Neither of these two patients used concomitant DMARDs.</p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p>In this study, we assessed the potential relevance of serum drug levels and ADAbs on various aspects of clinical response to adalimumab treatment in pSpA. The major findings are that (1) trough serum adalimumab levels were heterogeneous but did not correlate with clinical response to treatment or relapse after anti-TNF treatment discontinuation, (2) antiadalimumab ADAbs were found in one-fourth of the patients but also did not correlate with clinical response to treatment or relapse after discontinuation of the TNF inhibitor and (3) low-titre ADAbs could be masked by circulating adalimumab, but &#x02018;unmasked&#x02019; ADAbs showed no clear relationship with clinical efficacy.</p><p>More and more research is being done to address the immunogenicity of TNF inhibitors in various IMIDs, including SpA, because the development of ADAbs towards these TNF inhibitors are assumed to play a major role in loss of response to treatment. The mechanism behind this is thought to be either an increased clearance of the drug or neutralization of the active component of the compound
[<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. This hypothesis is supported by researchers in several studies of infliximab and adalimumab who reported that treatment failure occurred more often in patients who tested positive for ADAbs
[<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. However, there is also evidence which is not in line with this concept; in other studies of infliximab, investigators did not find a relation between ADAbs and response to treatment
[<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Moreover, in one of the studies in which researchers found serum trough infliximab levels to be significantly higher in responders than in nonresponders, although statistical significance was reached, the difference between these groups was very low (8.2&#x000a0;&#x003bc;g/ml vs. 6.3&#x000a0;&#x003bc;g/ml, respectively)
[<xref ref-type="bibr" rid="CR12">12</xref>]. Whether such a small difference is really clinically relevant is questionable. ADAbs towards etanercept have not been found, nor is there an association between serum drug levels and clinical effect
[<xref ref-type="bibr" rid="CR19">19</xref>]. Likewise, for golimumab, there is no clear relation between ADAbs and clinical efficacy
[<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, in a recent meta-analysis of various TNF inhibitors
[<xref ref-type="bibr" rid="CR22">22</xref>] and the clinical experience of there being no difference in efficacy or drug survival between the various TNF inhibitors
[<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], the authors also questioned the clinical relevance of anti-TNF ADAbs.</p><p>Several factors could be examined to develop an explanation of these differences between the various studies. First, not all TNF inhibitors are assumed to be equally immunogenic. For example, the soluble dimeric fusion protein etanercept has a less immunogenic structure because only the fusion part of the molecule can contain immunogenic epitopes. Also, it is administered more frequently than the other TNF inhibitors, thereby possibly creating more drug interference in ADAb detection
[<xref ref-type="bibr" rid="CR19">19</xref>]. However, this does not explain why researchers in different studies of the same TNF inhibitor (for example, infliximab) have come to different conclusions
[<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Second, there may be differences among the different SpA subtypes. However, even in studies of both the same disease and the same TNF inhibitor (for example, infliximab in AS), contradicting conclusions have been drawn
[<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Hence, this could also not explain why we and others
[<xref ref-type="bibr" rid="CR21">21</xref>] did not find a clinical association with anti-TNF drug levels or ADAbs in pSpA, whereas researchers in another study did conclude that these factors had clinical relevance
[<xref ref-type="bibr" rid="CR15">15</xref>]. Third, there is some variation in the size and duration of the studies, but this did not influence the results with regard to whether ADAbs did or did not have clinical relevance
[<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Fourth, the use of DMARDs, especially methotrexate, has been described to decrease the immunogenicity of TNF inhibitor trough, a mechanism which is not yet understood
[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. However, this is not in line with the finding that the addition of methotrexate in the management of SpA does not have an impact on the efficacy of the treatment
[<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] or on drug survival of the TNF inhibitor
[<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In our present study, we indeed found fewer of ADAbs in patients using DMARDs; however, this difference was no longer present when we analysed the &#x02018;unmasked ADAbs&#x02019;. Fifth, the detection of ADAbs is also influenced by the assay used. However, the method used in our present study is the same as that used in other studies
[<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], making it unlikely that this is the explanation for the differences in results. Seventh, the timing of the samples also influences the measurement of ADAbs because the assays are sensitive to drug interference, even when measured before the next administration of the drug, when the drug levels are the lowest
[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Indeed, we show here that when antiadalimumab ADAbs were measured at follow-up, after discontinuation of the TNF inhibitor, more patients tested positive than when antiadalimumab ADAbs were measured at the end of treatment. Previous researchers have reported that anti-TNF ADAb titres can decrease and increase over time, and vice versa
[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], causing a gradual increase in incidence over time when ADAb status is presented cumulatively, but not when assessed at each time point independently
[<xref ref-type="bibr" rid="CR33">33</xref>]. This shows that the timing of the measurement can influence the interpretation of ADAb status, making it very difficult to make strong conclusions about the relationship with clinical response and to apply ADAb measurement in clinical practise.</p><p>The limited number of patients is a limitation of our study. We thus cannot exclude that clinical correlation with serum adalimumab levels and/or ADAbs would be found in larger patient cohorts. However, this would imply that this association is weak and thus not relevant anyway for treatment monitoring in individual patients. Also, in one small study in which researchers investigated whether the serum trough infliximab levels modified therapeutic decisions in the management of AS, no improvement in the control of disease activity was found
[<xref ref-type="bibr" rid="CR34">34</xref>]. Similar efficacy and drug survival of TNF inhibitors&#x02014;those that induce ADAbs and those which do not
[<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] &#x02014;also raise questions about the relevance of testing the immunogenicity of these drugs. Although testing immunogenicity in clinical trials is standard practise and may yield interesting scientific insights, the real added value of the presence or absence of ADAbs in an individual patient in clinical practise remains to be demonstrated.</p></sec><sec id="Sec13" sec-type="conclusions"><title>Conclusions</title><p>The link between either serum adalimumab levels or antiadalimumab ADAbs and clinical response or relapse is not as strong as previously assumed. This argues against the use of these parameters in monitoring drug efficacy. Although treatment with adalimumab and other TNF inhibitors is very successful overall in SpA, future research has to be done to unravel factors which can explain differences in clinical response to further improve disease management by developing a personalized and more cost-effective approach.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>ADAbs</term><def><p>Antidrug antibodies</p></def></def-item><def-item><term>AS</term><def><p>Ankylosing spondylitis</p></def></def-item><def-item><term>ASDAS</term><def><p>Ankylosing Spondylitis Disease Activity Score</p></def></def-item><def-item><term>AU</term><def><p>Arbitrary units</p></def></def-item><def-item><term>BASDAI</term><def><p>Bath Ankylosing Spondylitis Disease Activity Index</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>DMARD</term><def><p>Disease-modifying antirheumatic drug</p></def></def-item><def-item><term>ELISA</term><def><p>Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>ESR</term><def><p>Erythrocyte sedimentation rate</p></def></def-item><def-item><term>ESSG</term><def><p>European Spondyloarthritis Study Group</p></def></def-item><def-item><term>IMID</term><def><p>Immune-mediated inflammatory disease</p></def></def-item><def-item><term>IQR</term><def><p>Interquartile range</p></def></def-item><def-item><term>NSAID</term><def><p>Nonsteroidal anti-inflammatory drug</p></def></def-item><def-item><term>PsA</term><def><p>Psoriatic arthritis</p></def></def-item><def-item><term>pSpA</term><def><p>Peripheral spondyloarthritis</p></def></def-item><def-item><term>RCT</term><def><p>Randomized controlled trial</p></def></def-item><def-item><term>SJC</term><def><p>Swollen joint count</p></def></def-item><def-item><term>SpA</term><def><p>Spondyloarthritis</p></def></def-item><def-item><term>TJC</term><def><p>Tender joint count</p></def></def-item><def-item><term>TNF</term><def><p>Tumour necrosis factor.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>Both authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>JEP participated in the conduct of the trial and the analysis and interpretation of the data, and drafted the manuscript. DLP contributed to the design of the trial interpretation of the data, and supervised the development of the manuscript. Both authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank AbbVie for the supply of the study medication for this investigator-initiated independent study. Also, we would like to thank TF Heijda and A van Tillo for their help in this study. Prof Dr. DL Baeten is supported by a Vidi grant from The Netherlands Organization for Scientific Research (NWO).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Bosch</surname><given-names>F</given-names></name><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Herssens</surname><given-names>A</given-names></name><name><surname>De Keyser</surname><given-names>F</given-names></name><name><surname>Mielants</surname><given-names>H</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name></person-group><article-title>Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor &#x003b1; (infliximab) versus placebo in active spondylarthropathy</article-title><source>Arthritis Rheum</source><year>2002</year><volume>46</volume><fpage>755</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1002/art.511</pub-id><pub-id pub-id-type="pmid">11920412</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Listing</surname><given-names>J</given-names></name><name><surname>Zink</surname><given-names>A</given-names></name><name><surname>Alten</surname><given-names>R</given-names></name><name><surname>Golder</surname><given-names>W</given-names></name><name><surname>Gromnica-Ihle</surname><given-names>E</given-names></name><name><surname>Kellner</surname><given-names>H</given-names></name><name><surname>Krause</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>S&#x000f6;rensen</surname><given-names>H</given-names></name><name><surname>Zeidler</surname><given-names>H</given-names></name><name><surname>Thriene</surname><given-names>W</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name></person-group><article-title>Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1187</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)08215-6</pub-id><pub-id pub-id-type="pmid">11955536</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoni</surname><given-names>C</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>de Vlam</surname><given-names>K</given-names></name><name><surname>Birbara</surname><given-names>C</given-names></name><name><surname>Beutler</surname><given-names>A</given-names></name><name><surname>Guzzo</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Dooley</surname><given-names>LT</given-names></name><name><surname>Kavanaugh</surname><given-names>A</given-names></name><collab>for the IMPACT 2 investigators</collab></person-group><article-title>Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><fpage>1150</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1136/ard.2004.032268</pub-id><pub-id pub-id-type="pmid">15677701</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Mease</surname><given-names>PJ</given-names></name><name><surname>Maksymowych</surname><given-names>WP</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Arora</surname><given-names>V</given-names></name><name><surname>Pangan</surname><given-names>AL</given-names></name></person-group><article-title>Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>815</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-201766</pub-id><pub-id pub-id-type="pmid">22772328</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paramarta</surname><given-names>JE</given-names></name><name><surname>De Rycke</surname><given-names>L</given-names></name><name><surname>Heijda</surname><given-names>TF</given-names></name><name><surname>Ambarus</surname><given-names>CA</given-names></name><name><surname>Vos</surname><given-names>K</given-names></name><name><surname>Dinant</surname><given-names>HJ</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Baeten</surname><given-names>DL</given-names></name></person-group><article-title>Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>1793</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202245</pub-id><pub-id pub-id-type="pmid">23139265</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Laken</surname><given-names>CJ</given-names></name><name><surname>Voskuyl</surname><given-names>AE</given-names></name><name><surname>Roos</surname><given-names>JC</given-names></name><name><surname>Stigter Van Walsum</surname><given-names>M</given-names></name><name><surname>de Groot</surname><given-names>ER</given-names></name><name><surname>Wolbink</surname><given-names>G</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name></person-group><article-title>Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>253</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1136/ard.2006.057406</pub-id><pub-id pub-id-type="pmid">16793840</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Schouwenburg</surname><given-names>PA</given-names></name><name><surname>van de Stadt</surname><given-names>LA</given-names></name><name><surname>de Jong</surname><given-names>RN</given-names></name><name><surname>van Buren</surname><given-names>EE</given-names></name><name><surname>Kruithof</surname><given-names>S</given-names></name><name><surname>de Groot</surname><given-names>E</given-names></name><name><surname>Hart</surname><given-names>M</given-names></name><name><surname>van Ham</surname><given-names>SM</given-names></name><name><surname>Rispens</surname><given-names>T</given-names></name><name><surname>Aarden</surname><given-names>L</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name><name><surname>Wouters</surname><given-names>D</given-names></name></person-group><article-title>Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-201445</pub-id><pub-id pub-id-type="pmid">22759910</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>FB</given-names></name><name><surname>Morand</surname><given-names>EF</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Mackay</surname><given-names>F</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name><name><surname>Marcelli</surname><given-names>C</given-names></name></person-group><article-title>Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>165</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202545</pub-id><pub-id pub-id-type="pmid">23178294</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ea;s</surname><given-names>S</given-names></name><name><surname>Demengeot</surname><given-names>J</given-names></name><name><surname>Benito-Garcia</surname><given-names>E</given-names></name></person-group><article-title>The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>1947</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202220</pub-id><pub-id pub-id-type="pmid">23223420</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arends</surname><given-names>S</given-names></name><name><surname>Lebbink</surname><given-names>HR</given-names></name><name><surname>Spoorenberg</surname><given-names>A</given-names></name><name><surname>Bungener</surname><given-names>LB</given-names></name><name><surname>Roozendaal</surname><given-names>C</given-names></name><name><surname>van der Veer</surname><given-names>E</given-names></name><name><surname>Houtman</surname><given-names>PM</given-names></name><name><surname>Griep</surname><given-names>EN</given-names></name><name><surname>Limburg</surname><given-names>PC</given-names></name><name><surname>Kallenberg</surname><given-names>CG</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name><name><surname>Brouwer</surname><given-names>E</given-names></name></person-group><article-title>The formation of autoantibodies and antibodies to TNF-&#x003b1; blocking agents in relation to clinical response in patients with ankylosing spondylitis</article-title><source>Clin Exp Rheumatol</source><year>2010</year><volume>28</volume><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">20822711</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>MK</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name><name><surname>Stapel</surname><given-names>SO</given-names></name><name><surname>de Groot</surname><given-names>ER</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>van der Horst-Bruinsma</surname><given-names>IE</given-names></name></person-group><article-title>Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>133</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1136/ard.2006.057745</pub-id><pub-id pub-id-type="pmid">17178760</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>MK</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name><name><surname>Stapel</surname><given-names>SO</given-names></name><name><surname>de Vrieze</surname><given-names>H</given-names></name><name><surname>van Denderen</surname><given-names>JC</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>van der Horst-Bruinsma</surname><given-names>IE</given-names></name></person-group><article-title>Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>1252</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1136/ard.2007.072397</pub-id><pub-id pub-id-type="pmid">17472991</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducourau</surname><given-names>E</given-names></name><name><surname>Mulleman</surname><given-names>D</given-names></name><name><surname>Paintaud</surname><given-names>G</given-names></name><name><surname>Miow Lin</surname><given-names>DC</given-names></name><name><surname>Lauf&#x000e9;ron</surname><given-names>F</given-names></name><name><surname>Ternant</surname><given-names>D</given-names></name><name><surname>Watier</surname><given-names>H</given-names></name><name><surname>Goupille</surname><given-names>P</given-names></name></person-group><article-title>Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases</article-title><source>Arthritis Res Ther</source><year>2011</year><volume>13</volume><fpage>R105</fpage><pub-id pub-id-type="doi">10.1186/ar3386</pub-id><pub-id pub-id-type="pmid">21708018</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plasencia</surname><given-names>C</given-names></name><name><surname>Pascual-Salcedo</surname><given-names>D</given-names></name><name><surname>Nu&#x000f1;o</surname><given-names>L</given-names></name><name><surname>Bonilla</surname><given-names>G</given-names></name><name><surname>Villalba</surname><given-names>A</given-names></name><name><surname>Peiteado</surname><given-names>D</given-names></name><name><surname>D&#x000ed;ez</surname><given-names>J</given-names></name><name><surname>Nagore</surname><given-names>D</given-names></name><name><surname>del Agua</surname><given-names>AR</given-names></name><name><surname>Moral</surname><given-names>R</given-names></name><name><surname>Martin-Mola</surname><given-names>E</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name></person-group><article-title>Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab</article-title><source>Ann Rheum Dis</source><year>2012</year><volume>71</volume><fpage>1955</fpage><lpage>1960</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2011-200828</pub-id><pub-id pub-id-type="pmid">22563028</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kuijk</surname><given-names>AW</given-names></name><name><surname>de Groot</surname><given-names>M</given-names></name><name><surname>Stapel</surname><given-names>SO</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name></person-group><article-title>Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><fpage>624</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.108787</pub-id><pub-id pub-id-type="pmid">20223840</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>MK</given-names></name><name><surname>Brouwer</surname><given-names>E</given-names></name><name><surname>van der Horst-Bruinsma</surname><given-names>IE</given-names></name><name><surname>Spoorenberg</surname><given-names>A</given-names></name><name><surname>van Denderen</surname><given-names>JC</given-names></name><name><surname>Jamnitski</surname><given-names>A</given-names></name><name><surname>Nurmohamed</surname><given-names>MT</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name></person-group><article-title>Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><fpage>1787</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.109702</pub-id><pub-id pub-id-type="pmid">19822712</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baraliakos</surname><given-names>X</given-names></name><name><surname>Listing</surname><given-names>J</given-names></name><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Alten</surname><given-names>R</given-names></name><name><surname>Burmester</surname><given-names>G</given-names></name><name><surname>Gromnica-Ihle</surname><given-names>E</given-names></name><name><surname>Haibel</surname><given-names>H</given-names></name><name><surname>Schewe</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>S&#x000f6;rensen</surname><given-names>H</given-names></name><name><surname>Zeidler</surname><given-names>H</given-names></name><name><surname>Visvanathan</surname><given-names>S</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name></person-group><article-title>Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis</article-title><source>J Rheumatol</source><year>2007</year><volume>34</volume><fpage>510</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">17299842</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krzysiek</surname><given-names>R</given-names></name><name><surname>Breban</surname><given-names>M</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><name><surname>Prejean</surname><given-names>MV</given-names></name><name><surname>Wijdenes</surname><given-names>J</given-names></name><name><surname>Roy</surname><given-names>C</given-names></name><name><surname>Henry</surname><given-names>YD</given-names></name><name><surname>Barbey</surname><given-names>C</given-names></name><name><surname>Trappe</surname><given-names>G</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Emilie</surname><given-names>D</given-names></name><collab>French Ankylosing Spondylitis Infliximab Network</collab></person-group><article-title>Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study</article-title><source>Arthritis Rheum</source><year>2009</year><volume>61</volume><fpage>569</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1002/art.24275</pub-id><pub-id pub-id-type="pmid">19405015</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>MK</given-names></name><name><surname>van der Horst-Bruinsma</surname><given-names>IE</given-names></name><name><surname>Nurmohamed</surname><given-names>MT</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>Stapel</surname><given-names>SO</given-names></name><name><surname>Peters</surname><given-names>MJ</given-names></name><name><surname>van Denderen</surname><given-names>JC</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name></person-group><article-title>Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><fpage>531</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1136/ard.2008.089979</pub-id><pub-id pub-id-type="pmid">18375542</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inman</surname><given-names>RD</given-names></name><name><surname>Davis</surname><given-names>JC</given-names><suffix>Jr</suffix></name><name><surname>Heijde</surname><given-names>D</given-names></name><name><surname>Diekman</surname><given-names>L</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SI</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Visvanathan</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Hsu</surname><given-names>B</given-names></name><name><surname>Beutler</surname><given-names>A</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name></person-group><article-title>Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>3402</fpage><lpage>3412</lpage><pub-id pub-id-type="doi">10.1002/art.23969</pub-id><pub-id pub-id-type="pmid">18975305</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>McInnes</surname><given-names>I</given-names></name><name><surname>Mease</surname><given-names>P</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Gomez-Reino</surname><given-names>J</given-names></name><name><surname>Papp</surname><given-names>K</given-names></name><name><surname>Zrubek</surname><given-names>J</given-names></name><name><surname>Mudivarthy</surname><given-names>S</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Visvanathan</surname><given-names>S</given-names></name><name><surname>Beutler</surname><given-names>A</given-names></name></person-group><article-title>Golimumab, a new human tumor necrosis factor &#x003b1; antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><fpage>976</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1002/art.24403</pub-id><pub-id pub-id-type="pmid">19333944</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maneiro</surname><given-names>JR</given-names></name><name><surname>Salgado</surname><given-names>E</given-names></name><name><surname>Gomez-Reino</surname><given-names>JJ</given-names></name></person-group><article-title>Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis</article-title><source>JAMA Intern Med</source><year>2013</year><volume>173</volume><fpage>1416</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2013.7430</pub-id><pub-id pub-id-type="pmid">23797343</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glintborg</surname><given-names>B</given-names></name><name><surname>Ostergaard</surname><given-names>M</given-names></name><name><surname>Krogh</surname><given-names>NS</given-names></name><name><surname>Andersen</surname><given-names>MD</given-names></name><name><surname>Tarp</surname><given-names>U</given-names></name><name><surname>Loft</surname><given-names>AG</given-names></name><name><surname>Lindegaard</surname><given-names>HM</given-names></name><name><surname>Holland-Fischer</surname><given-names>M</given-names></name><name><surname>Nordin</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>DV</given-names></name><name><surname>Olsen</surname><given-names>CH</given-names></name><name><surname>Hetland</surname><given-names>ML</given-names></name></person-group><article-title>Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor &#x003b1; inhibitor therapy: results from the Danish Nationwide DANBIO Registry</article-title><source>Arthritis Rheum</source><year>2013</year><volume>65</volume><fpage>1213</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1002/art.37876</pub-id><pub-id pub-id-type="pmid">23460467</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glintborg</surname><given-names>B</given-names></name><name><surname>Ostergaard</surname><given-names>M</given-names></name><name><surname>Krogh</surname><given-names>NS</given-names></name><name><surname>Dreyer</surname><given-names>L</given-names></name><name><surname>Kristensen</surname><given-names>HL</given-names></name><name><surname>Hetland</surname><given-names>ML</given-names></name></person-group><article-title>Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years&#x02019; surveillance in the Danish nationwide DANBIO registry</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><fpage>2002</fpage><lpage>2008</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.124446</pub-id><pub-id pub-id-type="pmid">20511613</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Schouwenburg</surname><given-names>PA</given-names></name><name><surname>Bartelds</surname><given-names>GM</given-names></name><name><surname>Hart</surname><given-names>MH</given-names></name><name><surname>Aarden</surname><given-names>L</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name><name><surname>Wouters</surname><given-names>D</given-names></name></person-group><article-title>A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients</article-title><source>J Immunol Methods</source><year>2010</year><volume>362</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2010.09.005</pub-id><pub-id pub-id-type="pmid">20833178</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>van der Linden</surname><given-names>S</given-names></name><name><surname>Juhlin</surname><given-names>R</given-names></name><name><surname>Huitfeldt</surname><given-names>B</given-names></name><name><surname>Amor</surname><given-names>B</given-names></name><name><surname>Calin</surname><given-names>A</given-names></name><name><surname>Cats</surname><given-names>A</given-names></name><name><surname>Dijkmans</surname><given-names>B</given-names></name><name><surname>Olivieri</surname><given-names>I</given-names></name><name><surname>Pasero</surname><given-names>G</given-names></name><name><surname>Veys</surname><given-names>E</given-names></name><name><surname>Zeidler</surname><given-names>H</given-names></name></person-group><article-title>The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy</article-title><source>Arthritis Rheum</source><year>1991</year><volume>34</volume><fpage>1218</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1002/art.1780341003</pub-id><pub-id pub-id-type="pmid">1930310</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amor</surname><given-names>B</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Mijiyawa</surname><given-names>M</given-names></name></person-group><article-title>[Criteria of the classification of spondylarthropathies] [in French]</article-title><source>Rev Rhum Mal Osteoartic</source><year>1990</year><volume>57</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">2181618</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>P</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>R</given-names></name><name><surname>Lie</surname><given-names>E</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><collab>for the Assessment of SpondyloArthritis International Society</collab></person-group><article-title>Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.138594</pub-id><pub-id pub-id-type="pmid">21068095</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paramarta</surname><given-names>JE</given-names></name><name><surname>Heijda</surname><given-names>TF</given-names></name><name><surname>Baeten</surname><given-names>DL</given-names></name></person-group><article-title>Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>1581</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203327</pub-id><pub-id pub-id-type="pmid">23661496</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartelds</surname><given-names>GM</given-names></name><name><surname>Krieckaert</surname><given-names>CL</given-names></name><name><surname>Nurmohamed</surname><given-names>MT</given-names></name><name><surname>van Schouwenburg</surname><given-names>PA</given-names></name><name><surname>Lems</surname><given-names>WF</given-names></name><name><surname>Twisk</surname><given-names>JW</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Aarden</surname><given-names>L</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name></person-group><article-title>Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>1460</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.406</pub-id><pub-id pub-id-type="pmid">21486979</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jani</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Warren</surname><given-names>RB</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Chinoy</surname><given-names>H</given-names></name></person-group><article-title>The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases</article-title><source>Rheumatology (Oxford)</source><year>2014</year><volume>53</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ket260</pub-id><pub-id pub-id-type="pmid">23946436</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagerli</surname><given-names>KM</given-names></name><name><surname>Lie</surname><given-names>E</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Heiberg</surname><given-names>MS</given-names></name><name><surname>Lexberg</surname><given-names>AS</given-names></name><name><surname>R&#x000f8;devand</surname><given-names>E</given-names></name><name><surname>Kalstad</surname><given-names>S</given-names></name><name><surname>Mikkelsen</surname><given-names>K</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name></person-group><article-title>The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study</article-title><source>Ann Rheum Dis</source><year>2014</year><volume>73</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202347</pub-id><pub-id pub-id-type="pmid">23291385</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanauer</surname><given-names>SB</given-names></name><name><surname>Wagner</surname><given-names>CL</given-names></name><name><surname>Bala</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>L</given-names></name><name><surname>Travers</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>RH</given-names></name><name><surname>Olson</surname><given-names>A</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name></person-group><article-title>Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn&#x02019;s disease</article-title><source>Clin Gastroenterol Hepatol</source><year>2004</year><volume>2</volume><fpage>542</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/S1542-3565(04)00238-1</pub-id><pub-id pub-id-type="pmid">15224278</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;ric</surname><given-names>JC</given-names></name><name><surname>Mulleman</surname><given-names>D</given-names></name><name><surname>Ducourau</surname><given-names>E</given-names></name><name><surname>Lauf&#x000e9;ron</surname><given-names>F</given-names></name><name><surname>Miow Lin</surname><given-names>DC</given-names></name><name><surname>Watier</surname><given-names>H</given-names></name><name><surname>Goupille</surname><given-names>P</given-names></name><name><surname>Paintaud</surname><given-names>G</given-names></name></person-group><article-title>Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study</article-title><source>Ther Drug Monit</source><year>2011</year><volume>33</volume><fpage>411</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e318224f83d</pub-id><pub-id pub-id-type="pmid">21743380</pub-id></element-citation></ref></ref-list></back></article>